June 2, 2022 10:54 AM EDTUpdated 02:13 PM
Marketing

Bio­gen, Sam­sung Bioepis look to carve up a block­buster Roche fran­chise with deep dis­count biosim­i­lar

John Carroll

Editor & Founder

Bio­gen and their biosim­i­lar part­ners at Sam­sung Bioepis are rolling out their copy­cat ver­sion of Roche’s an­ti-VEGF block­buster Lu­cen­tis to­day, 8 months af­ter it was …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times